| Mar 12, 2011 | |
New nanomaterials for regenerative medicine is to be discussed at Pharmaceutical Nanotechnology conference |
|
| (Nanowerk News) Nanotechnology is a multidisciplinary scientific field that is currently undergoing explosive development. Nano-enhanced medicines are opening new opportunities for therapeutic delivery and targeting, technology is also allowing agents that previously could not be used effectively as conventional formulations due to poor bioavailability or drug instability to advance into clinical development. However, there are still a number of concerns remaining concerning toxicological aspects and ethical implications. | |
| SMi is proud to present their Pharmaceutical Nanotechnology: Applications & Commercialisation conference, taking place in London on 29th and 30th June, 2011. | |
| Key Presentations Include: | |
|
The business case for nanotechnology Thomas Keller, Director, Open Innovation, GlaxoSmithKline |
|
|
Miniaturisation and modelling of beads milling Mostafa Nakach, Head of Pharmaceutical Engineering Group, Sanofi-Aventis R&D |
|
|
Investigation of chitosan nanoparticle formulations Michael Keller, Senior Fellow, siRNA Project Leader, Technical Research and Development (TRD), Novartis Pharma |
|
|
Enabling oncology drug development with nanotechnology Henry Havel, Senior Research Fellow, Product Research and Development, Eli Lilly and company |
|
|
Industry partnering opportunities, open innovation, one solution Peter Luke, Senior Director, R&D Business Development, Worldwide Business Development, Pfizer |
|
| For more information and to download the brochure visit www.smi-online.co.uk/nanotech27.asp |
| Source: SMI Group |